The performance of clinical analyzers is commonly assessed under a variety of environmental conditions to set acceptable limits (e.g., temperature and humidity) for operation. We recently faced an unusual environmental challenge within our automation laboratory, namely a variable magnetic field emanating from a Niobe Magnetic Navigation System (Stereotaxis; http:// www.stereotaxis.com) being installed in the cardiac catheter laboratory immediately above our laboratory. The system contains 2 strong permanent magnets that generate magnetic fields of 0.08 -0.1 T (800 -1000 G) in any direction. When the magnets are in the stowed position, the maximum magnetic field is 0.2 T (2000 G). Although more prominent for other medical devices, the permissible magnetic field strength is not an environmental variable usually considered by manufacturers of clinical analyzers (1, 2 ).
We thus faced a multifaceted problem: On the day of the magnet delivery, we had to assess its effects on all of the analyzers within our automation laboratory, and we had to assess its effects on replacement analyzers due to be installed in the following weeks. Accordingly, we needed to assess the effects of a variable magnetic field on the accuracy and precision of the current and future clinical analyzers within our automation laboratory (Beckman Coulter DxI, DxC 800, LH 780, and LH 755; Ortho Clinical Diagnostics/Johnson & Johnson Vitros 950AT; Roche Diagnostics Modular Analytics P Module; Siemens UF-100; bioMérieux MDA; Siemens SMS Immulite 2500; Abbott Diagnostics AxSYM; bioMérieux mini VIDAS), in particular those that used magnetic particle-based reagents (Immulite 2500). We had replaced all cathode ray tube displays in the laboratory with liquid crystal display screens before magnet installation because the expected magnetic field was known to interfere with cathode ray tube operation.
Our assessment study included repeated replicate analyses of QC materials (high, medium, and low concentrations of each analyte) before installation of the magnet, in the presence of the relatively low and constant magnetic field when the magnets were stowed, and in the much higher but transient magnetic field when the magnets were in motion. To eliminate any bias due to the vested interests of either the clinical laboratory or the catheter laboratory, we had an independent external consultant supervise the evaluation and analyze the data.
Our goal was to determine whether a statistically significant change in results occurred after the magnet was installed. Given the number of experiments to be evaluated in a short period, we based our assessment on a 99% confidence level (rather than 95%). The highest magnetic field measured at any location in the laboratory when the magnets were stowed or moving was Ͻ1.26 G (Ͻ0.126 mT). This relatively weak field [occupational exposure levels designated by the In ternational Commission on NonIonizing Radiation Protection are 200 mT for continuous exposure and 2000 mT for short-term wholebody exposure (3 )] indicated that the shielding installed under the magnetic system was effective in protecting the analyzers in our laboratory from the magnetic field.
Data were captured and analyzed with EP Evaluator (David G. Rhoads Associates) and custom software. We evaluated changes in precision with the SD ratio (ratio of the postmagnet SD to the premagnet SD). We compared the SD ratio with a cutoff value, and if the ratio exceeded the cutoff, we concluded that a statistically significant change had occurred. The cutoff level was based on the sizes of the 2 samples being compared and the desired false-rejection rate (4 ). Smaller sample sizes have a larger cutoff value. For example, for 100 premagnet replicate tests and 20 postmagnet replicate tests, the 99% cutoff was 1.45. For 20 premagnet replicate tests and 20 postmagnet replicate tests, the cutoff was 1.74. Accuracy changes were judged from Levey-Jennings control charts covering the total testing period. The zero (target) line on this chart was set at the mean value observed during the first phase of testing, and the SD was the pooled within-batch SD over all phases.
We observed a significant difference based on the cutoff level in only 19 of 900 precision data sets; however, the observed statistically significant changes (measured in relation to the SD of the process) in mean test results before and after installation of the magnet were for tests with a very small SD (hence the statistically significant change). Although the change was statistically significant, it was not clinically important and thus not expected to have an adverse effect on patient safety or care. For example, results for replicate analyses of a control material for potassium gave a mean of 2.80 mmol/L and an SD of 0.02 mmol/L (CV, 0.7%). After installation of the magnet, we obtained a mean potassium value of 2.85 mmol/L and an SD of 0.05 mmol/L (CV, 1.7%). Although this change is statistically significant, it was not clinically meaningful.
Our studies confirmed that this external magnetic field had no clinically meaningful effect on the assays performed in our clinical laboratory, and the results provided a basis for continued operation in the presence of an unusual environmental factor.
More on Methanol-Associated Matrix Effects in Electrospray Ionization Mass Spectrometry

To the Editor:
Based on the observations reported by Annesley regarding methanolassociated matrix effects (1 ), I changed from the use of Burdick and Jackson (B&J) 1 to EMD Chemicals (EMD) methanol in the mobile phases for tacrolimus, cyclosporine, and sirolimus procedures that used electrospray ionization on single LC-MS and tandem quadrupole LC-MS (LC-MS/MS) instrument systems. Presented herein are observations that supplement Annesley's observations regarding the influence that brand of methanol can have on analytical performance.
I routinely performed tacrolimus and cyclosporine procedures using LC-MS/MS and sirolimus using LC-MS. The tacrolimus and cyclosporine procedures have been described previously (2, 3 ). The sirolimus procedures (unpublished data) were similar to the others. The same sample preparation was used for both LC-MS and LC-MS/MS analysis. Importantly, methanol supplemented with ammonium acetate and formic acid (prepared in and used directly from the manufacturer's bottle) was the LC-MS/MS mobile-phase organic component, in which ammonium adducts were monitored. For LC-MS methods we used methanol (directly from the manufacturer's bottle), and the aqueous component, water supplemented with sodium formate and formic acid, ensured sodium adduct signals for monitoring.
The change in brand of methanol from B&J to EMD did not affect the performance of the tacrolimus or cyclosporine LC-MS/MS assay, although cyclosporine and cyclosporin D (internal standard) peak areas increased moderately (15%). However, there was an immediate adverse effect on the sirolimus LC-MS procedure; performance worsened progressively until, on the sixth analytical run, the assay failed. Of note was the effect on the internal standard (ascomycin), for which the mean within-run peak height unexpectedly decreased between 10% and 36% from values in previous runs with B&J methanol. Peak height was used for tacrolimus and sirolimus LC-MS procedures because it reduced the need for manual reintegration, especially for samples with low concentration of analyte. Peak height was shown to provide performance specifications equivalent to peak area during method validation.
The within-run variation, a criterion for analytical run acceptance (i.e., Յ5%), was 9.1% initially, then 4.5%-7.3% subsequently. Fresh whole blood standard curve parameters were acceptable; however, the accuracy of the QC materials (fresh whole blood supplemented, divided
